Mycoplasma genitalium in US Sexually Transmitted Disease (STD) Clinics
S
Stephen Jordan
Primary Investigator
Enrolling By Invitation
18-100 years
All
Phase
N/A
800 participants needed
1 Location
Overview
The M. genitalium Surveillance Project has been designed to monitor trends in M. genitalium infection and resistance in high risk individuals attending sentinel sexually transmitted disease (STD) clinics in the United States over a 3-year period. The objectives are:
• To monitor the prevalence M. genitalium infection in symptomatic and asymptomatic persons and document changes over time.
• To monitor the prevalence of antimicrobial resistance to macrolides and quinolones in M. genitalium and document changes over time.
• To monitor the relative contribution of M. genitalium infection in persons with and without male and female reproductive tract disease syndromes and document changes over time.
Description
Samples will be obtained from BFC patients that are age 18 and older and have given the BFC written consent to have de-identified residual specimens stored and used for future research purposes; this consent process is standard for all BFC visits.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
M. genitalium, STD
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria:
- Remnant genitourinary specimens taken for gonorrhea and/or chlamydia, bacterial vaginosis and trichomonas vaginalis testing using the Aptima Combo2 assay from the first 100 asymptomatic men, 100 asymptomatic women, 100 symptomatic men and 100 symptomatic women during a collection cycle of up to 3 months will be selected. Selection will be based upon sex at birth rather than on gender identity. Alternatively, a site can choose to collect 800 samples annually:
- 200 asymptomatic men, 200 asymptomatic women, 200 symptomatic men and 200 symptomatic women.
- At least age 18.
Exclusion Criteria:
- Samples obtained that are not remnant genitourinary specimens, and/or specimens that were not taken for gonorrhea and/or chlamydia, bacterial vaginosis and trichomonas vaginalis testing while using the Aptima Combo2 assay.
- Age less than l8.
Updated on
15 May 2024.
Study ID: 2001598583, INFD-HOLOGIC-MG-SURVEILLANCE
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
